000131515 001__ 131515
000131515 005__ 20240228145604.0
000131515 0247_ $$2doi$$a10.1002/hed.24910
000131515 0247_ $$2pmid$$apmid:28945300
000131515 0247_ $$2ISSN$$a0148-6403
000131515 0247_ $$2ISSN$$a1043-3074
000131515 0247_ $$2ISSN$$a1097-0347
000131515 0247_ $$2altmetric$$aaltmetric:26559714
000131515 037__ $$aDKFZ-2017-06179
000131515 041__ $$aeng
000131515 082__ $$a610
000131515 1001_ $$00000-0001-5017-0815$$aHorn, Dominik$$b0
000131515 245__ $$aUpregulation of pAKT(Ser473) expression in progression of HPV-positive oropharyngeal squamous cell carcinoma.
000131515 260__ $$aNew York, NY [u.a.]$$bWiley Interscience$$c2017
000131515 3367_ $$2DRIVER$$aarticle
000131515 3367_ $$2DataCite$$aOutput Types/Journal article
000131515 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525858846_14346
000131515 3367_ $$2BibTeX$$aARTICLE
000131515 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131515 3367_ $$00$$2EndNote$$aJournal Article
000131515 520__ $$aPIK3CA alterations have been shown to be a frequent event in oropharyngeal squamous cell cancer (SCC), especially in human papillomavirus (HPV)-related tumors.Tissue microarrays (TMAs) were used to evaluate pAKT(Ser473)/(Thr308), total protein kinase B (AKT)(pan) and phosphatase and tensin homolog (PTEN) expression in primary tumors and corresponding nodal disease in oropharyngeal SCC. The HPV status was determined in regard of HPV16 DNA and RNA. Survival analysis was performed by using Kaplan-Meier curves, log-rank testing, and multivariate Cox regression analysis.HPV16 is a prognostic predictive marker for advanced oropharyngeal SCC. pAKT(Ser473) and PTEN are highly expressed in HPV-related oropharyngeal SCCs in contrast to pAKT(Thr308). The pAKT(Ser473) expression increased from primary tumors to progressive nodal disease (21.1%; P < .011).Activation of phosphoinositide 3-kinase (PI3K)/pAKT(Ser473) frequently occurs in advanced HPV-positive oropharyngeal SCC and elevated pAKT(Ser473) levels represent a feature during progression of oropharyngeal SCC, indicating a critical role of the mammalian target of rapamycin (mTOR) complex. Further studies are required to evaluate specific drugs targeting PI3K/AKT/mTOR in consideration of PIK3CA alterations.
000131515 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000131515 588__ $$aDataset connected to CrossRef, PubMed,
000131515 7001_ $$aFreudlsperger, Christian$$b1
000131515 7001_ $$0P:(DE-He78)d84ca2cd7f160904c387ee699735076c$$aHolzinger, Dana$$b2
000131515 7001_ $$aKunzmann, Kevin$$b3
000131515 7001_ $$0P:(DE-HGF)0$$aPlinkert, Peter$$b4
000131515 7001_ $$aDyckhoff, Gerhard$$b5
000131515 7001_ $$aHoffmann, Jürgen$$b6
000131515 7001_ $$aFreier, Kolja$$b7
000131515 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b8$$eLast author$$udkfz
000131515 773__ $$0PERI:(DE-600)2001440-5$$a10.1002/hed.24910$$gVol. 39, no. 12, p. 2397 - 2405$$n12$$p2397 - 2405$$tHead & neck$$v39$$x1043-3074$$y2017
000131515 909CO $$ooai:inrepo02.dkfz.de:131515$$pVDB
000131515 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d84ca2cd7f160904c387ee699735076c$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000131515 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000131515 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000131515 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000131515 9141_ $$y2017
000131515 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131515 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131515 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131515 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEAD NECK-J SCI SPEC : 2015
000131515 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131515 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131515 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131515 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131515 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131515 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131515 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131515 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000131515 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lMolekulare Diagnostik Oncogener Infektionen$$x0
000131515 9201_ $$0I:(DE-He78)A102-20160331$$kA102$$lMolekulare Grundlagen von HNO-Tumoren$$x1
000131515 980__ $$ajournal
000131515 980__ $$aVDB
000131515 980__ $$aI:(DE-He78)F020-20160331
000131515 980__ $$aI:(DE-He78)A102-20160331
000131515 980__ $$aUNRESTRICTED